Published ahead of print on August 11, 2004, doi:10.1164/rccm.200404-533OC
© 2004 American Thoracic Society doi: 10.1164/rccm.200404-533OC
Immunostimulatory Oligonucleotides Attenuate Airways Remodeling in Allergic MonkeysCenter for Comparative Respiratory Biology and Medicine, California National Primate Research Center, University of California, Davis; and School of Medicine, University of California, San Diego, California Correspondence and requests for reprints should be addressed to Michelle V. Fanucchi, Ph.D., Department of Anatomy, Physiology and Cell Biology, University of California, School of Veterinary Medicine, One Shields Avenue, Davis, CA 95616. E-mail: mvfanucchi{at}ucdavis.edu
To determine whether inhaled immunostimulatory DNA sequence oligonucleotides containing CpG motifs mitigate the pathophysiologic manifestation of the asthmatic phenotype (airways hyperresponsiveness and airways remodeling), rhesus monkeys with experimentally induced allergic airways disease were treated seven times with inhaled immunostimulatory oligonucleotides (or sham) periodically for 33 weeks. Airways hyperresponsiveness was reduced twofold in immunostimulatory DNA sequence–treated compared with sham-treated monkeys. Airways from immunostimulatory oligonucleotide-treated monkeys had thinner reticular basement membranes, fewer mucous cells, fewer eosinophils, and fewer mast cells than sham-treated allergic monkeys. We conclude that inhaled immunostimulatory oligonucleotides can attenuate the magnitude of airway hyperreactivity and airways remodeling produced in nonhuman primates with experimentally induced allergic airways disease.
Key Words: airway wall alterations • allergic asthma • immunostimulatory DNA sequence oligonucleotides • nonhuman primate Immunostimulatory DNA sequences (ISS) contain a CpG dinuncleotide (CpG motif) that is characteristic of bacterial DNA but relatively rare in vertebrate DNA. Vertebrate innate immune systems can rapidly detect infection using pattern recognition receptors (that include the toll-like receptors on dendritic cells, macrophages, monocytes, and neutrophils. Once bound, these receptors activate the immune system to respond specifically to infection (1–4). ISS treatment (by systemic or mucosal delivery) has been shown to inhibit airways remodeling and airways hyperresponsiveness in murine models (5–10). We have previously defined a nonhuman primate model of allergic asthma using aerosolized house dust mite allergen (HDMA) (Dermatophagoides farinae), a known human allergen (11). This model exhibits the hallmarks of allergic asthma defined by the 1997 National Heart, Lung, and Blood Institute National Asthma Education and Prevention Program, including positive skin tests, bronchial hyperresponsiveness, airway inflammation, and airways remodeling. To determine whether inhaled ISS mitigates the asthmatic phenotype (airways hyperresponsiveness and airways remodeling), rhesus monkeys with experimentally induced allergic airways disease were treated seven times with inhaled ISS (or sham) periodically for 33 weeks. Airways hypperresponsivenes was reduced in ISS-treated compared with sham-treated monkeys. Airways from ISS-treated monkeys had thinner basement membranes, fewer mucous cells, fewer eosinophils, and fewer mast cells than sham-treated monkeys. We conclude that inhaled ISS can attenuate the occurrence of airways hyperresponsiveness and airways remodeling in nonhuman primates with allergic disease. Some of the results of these studies have been previously reported in the form of abstracts (12, 13).
Animal Protocol Eight young adult (3–5 years old) rhesus macaques were sensitized and exposed to HDMA (D. farninae) for 11 weeks, as previously described (11). All eight monkeys demonstrated positive skin tests to HDMA. Differences between groups were analyzed by t test (17). After the HDMA sensitization, each monkey was exposed to HDMA aerosol once every 2 weeks for 20 weeks of exposure. Once all eight monkeys were determined to exhibit clinical and immunologic signs of allergic airways disease (confirmed by pulmonary function testing and bronchoalveolar lavage), the monkeys were sedated with ketamine and four of the eight monkeys were given three inhalation exposures (via facemask) of 12.5 mg ISS in 5 ml of sterile phosphate-buffered saline (PBS) over 6 weeks. Each ISS exposure occurred 24 hours before the HDMA exposure. The oligodeoxynucleotide sequence 5'-TGACTGTGAACGTTCGAGATGA-3' (10, 18) was used for this study; this sequence has been previously shown to be an effective immune stimulus for both mice and humans (10, 14). The remaining four monkeys received only sterile PBS (sham treatment). Biweekly HDMA exposures continued after these three ISS treatments for 12 weeks, during which time clinical signs of allergic airways disease were monitored by pulmonary function testing and bronchoalveolar lavage. An additional four inhalation exposures of 1.25 mg ISS in 5 ml of sterile PBS were delivered as previously described.
Pulmonary Mechanics and Airway Responsiveness Testing
Bronchoalveolar Lavage and Differential Cell Counts
Evaluation of Airways Remodeling
Quantitation of Immune Cells
Clinical Signs of Atopy and Allergic Asthma Inhaled ISS exposure altered clinical signs of atopy and allergic asthma in our HDMA-sensitized nonhuman primates. All eight monkeys in this study mounted a positive IgE response to a skin prick test for HDMA after 21 weeks of episodic HDMA challenge and before the start of ISS administration (Table 1). After three ISS treatments over 6 weeks, only one of four ISS-treated animals retained a positive skin-prick test to HDMA, whereas four of four sham-treated animals retained a positive skin-prick test to HDMA, indicating a loss of systemic IgE response in the ISS-treated monkeys. There were no significant changes in the levels of circulating eosinophils or systemic HDMA-specific IgE between sham- and ISS-treated asthmatic monkeys. Pulmonary function measurements were also altered after ISS treatment. Airway responsiveness was measured as the effective concentration of histamine required to produce a 150% increase in airways resistance (EC150) or a 50% decrease in dynamic lung compliance (EC50). Treatment with ISS resulted in a significant decrease in airways hyperresponsiveness to nonspecific stimuli as measured by EC150 (Figure 1A) and EC50 (Figure 1B) values as compared with sham-treated monkeys.
To assess the acute inflammation in response to an allergen challenge, we compared airway immune cell infiltrate 24 hours after HDMA aerosol challenge by bronchoalveolar lavage after 21 weeks of episodic allergen challenge (but before the start of the sham/ISS treatment). There was no significant difference in the magnitude or distribution of immune cells from the bronchoalveolar lavage in the eight monkeys, indicating that, although our sample size was small, our population was homogenous. The presham/pre-ISS treatment lavage samples consisted of a majority of macrophages followed in number by eosinophils, lymphocytes, and neutrophils (data not shown). After three ISS/sham treatments (Week 27), total airway leukocyte numbers after HDMA aerosol challenge were significantly reduced in ISS monkeys as compared with sham-treated monkeys (Figure 1C). In sham-treated monkeys, macrophages and neutrophils were the most abundant cell type in the lavage, whereas in ISS-treated animals the majority of cells were macrophages (Figure 1C). ISS treatment significantly decreased the number of lavage eosinophils and lymphocytes.
Airways Remodeling
Using HDMA-sensitized and challenged rhesus monkeys, we tested the hypothesis that ISS containing CpG motifs can attenuate airway hyperresponsiveness and airways remodeling, and diminish immediate-type hypersensitivity responses to allergen. Conceptually, the airways can be thought of as epithelial–mesenchymal trophic units comprised of epithelium lining the airway lumen attached to a basement membrane that is surrounded by layers of attenuated fibroblasts, extracellular matrix, and smooth muscle. The immune and nervous systems are interspersed throughout these components. The maintenance of normal communication between the epithelium and the mesenchymal components of the trophic unit, via the controlled release and production of signaling molecules, is critical to the preservation of normal structure and organization (19). Alterations of the airway trophic unit in asthma are reported as airways remodeling including (1) mucous cell hyperplasia; (2) reticular basement membrane thickening; (3) peribronchiolar or subbasement membrane fibrosis; and (4) smooth muscle hypertrophy (20–23). The pulmonary mucosa, airway wall structure, and systemic immune system of the adult rhesus monkey are similar to that of humans (24–27), and the same hallmarks of human allergic asthma are evident in the HDMA rhesus monkey model (11). Mouse models have provided much insight into the immunologic mechanisms of allergic asthma and the potential for ISS to alleviate them. In mice, both systemic (7, 9, 10, 28, 29) and mucosal (8) CpG oligonucleotide treatments have been shown to reduce clinical symptoms, such as airways hyperresponsiveness and airway eosinophilia, after inhaled ovalbumin administration. Evaluations of the ability of CpG motifs to attenuate airways remodeling in mice have not been as complete. Both mucosal and systemic ISS have been reported to reduce/prevent mucous cell metaplasia in mice exposed to inhaled ovalbumin (8, 9, 28, 29). However, this aspect of airways remodeling in mice does not accurately reflect the manifestation in humans. Normal bronchial epithelium in humans consists of  25% mucous (goblet) cells, whereas bronchial epithelium in mice consists of only 1% mucous (goblet) cells (reviewed in [27]). This means that an increase in mucous cells in human airways during an inflammatory response is most likely due to proliferation and hyperplasia of existing cells, whereas an increase in mucous cells in mice is most likely due to a metaplastic change. Systemic CpG oligonucleotide treatment in mice has also been shown to reduce peribronchiolar or subbasement membrane fibrosis (9, 28) and peribronchiolar smooth muscle thickness or hypertrophy (28) associated with allergic asthma. We did not observe clearly detectable differences in smooth muscle mass or bundle orientation between sham- or ISS-treated monkeys with asthma. This may be due in part to the relatively short-term nature of the ISS treatment in this study. Another reason may be the relative lack of plasticity of the smooth muscle in an adult animal. No information on reticular basement membrane thickening, an integral aspect of airways remodeling in asthma, is available from murine models of asthma or from treatment with CpG motifs. The reticular basement membrane is very thin in the relatively small airways of the mouse and difficult to study at the light microscopic level. In our nonhuman primate model of allergic asthma, however, we have shown that mucosal administration of ISS mitigates mucous cell hyperplasia (bronchial epithelium of rhesus monkeys has baseline levels of mucous [goblet] cells) and reticular basement membrane thickening, in addition to mitigating mast cell and eosinophilic infiltration. Differences in the gross and subgross anatomy of the lungs (25), architecture of the tracheobronchial trees (26), epithelial composition and distribution (24, 27), and secretory glycoconjugate composition (30) between primates and rodents make extrapolation of murine ovalbumin models to humans difficult. The present study shows that biweekly administration of inhaled ISS can mitigate mast cell and eosinophil infiltration, mucus-cell hyperplasia, reticular basement membrane thickening, and airway hyperresponsiveness associated with allergic airways disease in an animal model that closely reflects the pathophysiology of human asthma.
: The authors thank Sarah Davis and Brian Tarkington, as well as the animal care staff of the California National Primate Research Center, for all of their help and support for this project, and acknowledge Dynavax Technologies Corporation, Berkeley, CA for the gift of ISS and the editorial expertise of Dr. Suzette Smiley-Jewell.
Supported by National Institutes of Health grants ES00628, ES05707, RR00169, and AI40628. This article has an online supplement, which is accessible from this issue's table of contents at www.atsjournals.org Conflict of Interest Statement: M.V.F. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript; E.S.S. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript; G.L.B. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript; M.J.E. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript; R.J.M. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript; L.J.G. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript; E.R. is a founder of Dynavax, has 300,000 shares of stock in this company, and his lab was sponsored by this company from 1998–2003 at $500,000 per year; D.M.H. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript; C.G.P. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript; L.A.M. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. The University of California, San Diego is the owner of the patent related to the use of ISS for asthma. Received in original form April 23, 2004; accepted in final form August 6, 2004
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
TOP
ABSTRACT
METHODS
significantly different than sham-treated monkeys (p < 0.10). Inflammatory cells in lavage fluid in HDMA-sensitized monkeys is decreased by ISS (C). Data are expressed as mean ± SE of individual cell types. 
Significantly different from sham-treated monkeys (p < 0.025). PMN = polymorphonuclear leukocytes.